title: Characterization of neural estrogen signaling and neurotrophic changes in the accelerated ovarian failure mouse model of menopause.
abstract: Accelerated ovarian failure (AOF) can be induced in young mice with low doses of 4-vinylcyclohexene diepoxide (VCD), modeling the hormone changes observed across menopause. We assessed markers of synaptic plasticity in the hippocampus, anxiety-like behavior, and spatial learning longitudinally at 4 time points across the AOF model: premenopause, early perimenopause, late perimenopause, and postmenopause (POST). As others have shown, VCD administration decreased ovarian follicle counts and increased acyclicity as the model progressed to POST but with no impact on organ or body weights. The morphology of Iba1 immunoreactive microglia did not differ between vehicle- and VCD-administered mice. Hippocampal postsynaptic density 95 levels were minimally altered across the AOF model but decreased at POST in CA3b 24 hours after exogenous estradiol benzoate (EB). In contrast, hippocampal phosphorylated AKT levels transiently decreased in premenopause but increased at POST after 24 hours of EB in select subregions. Electron microscopy revealed fewer estrogen receptor α containing dendritic spines and terminals in CA1 stratum radiatum at POST. mRNA levels of most brain-derived neurotrophic factor exons (except V and VI) were lower in POST compared with ovariectomized mice. Exon V was sensitive to 24 hours of EB administration in POST-VCD. Anxiety-like behavior was unaffected at any menopause phase. Spatial learning was unaffected in all groups, but POST-VCD mice performed below chance. Our results suggest that the AOF model is suitable for longitudinal studies of neurobiological changes across the menopause transition in mice. Our findings also point to complex interactions between estrogen receptors and pathways involved in synaptic plasticity.
authors.affiliation: Brain and Mind Research Institute (T.A.V.K., T.A.M.) and Graduate Program in Neuroscience (T.A.V.K., A.D.G.), Weill Cornell Medical College, and Laboratory of Neuroendocrinology (J.G., T.A.M., E.M.W.), The Rockefeller University, New York, New York 10065; and Department of Environmental and Molecular Health Sciences (F.S.), Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
authors.forename: Tracey A
authors.initials: TA
authors.lastname: Van Kempen
authors.forename: Jolanta
authors.initials: J
authors.lastname: Gorecka
authors.forename: Andreina D
authors.initials: AD
authors.lastname: Gonzalez
authors.forename: Fumio
authors.initials: F
authors.lastname: Soeda
authors.forename: Teresa A
authors.initials: TA
authors.lastname: Milner
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Waters
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D047628:Estrogen Receptor alpha / Q000235:genetics / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D006624:Hippocampus / Q000378:metabolism; D006801:Humans; D008593:Menopause / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D009414:Nerve Growth Factors / Q000235:genetics / Q000378:metabolism*; D016649:Primary Ovarian Insufficiency / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D047628:Estrogen Receptor alpha; D004967:Estrogens; D009414:Nerve Growth Factors